[
    [
        {
            "time": "2018-01-02",
            "original_text": "FDA approves Eli Lilly drug for thyroid, lung cancers driven by a genetic mutation",
            "features": {
                "keywords": [
                    "FDA",
                    "Eli Lilly",
                    "drug",
                    "thyroid",
                    "lung cancers",
                    "genetic mutation"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "FDA approves Eli Lilly drug for thyroid, lung cancers driven by a genetic mutation",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "NIAID to Test Gilead's Remdesivir together with Lilly's Olumiant for Coronavirus",
            "features": {
                "keywords": [
                    "NIAID",
                    "Gilead",
                    "Remdesivir",
                    "Lilly",
                    "Olumiant",
                    "Coronavirus"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "NIAID to Test Gilead's Remdesivir together with Lilly's Olumiant for Coronavirus",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Government to test remdesivir with Lilly drug in COVID-19 patients",
            "features": {
                "keywords": [
                    "Government",
                    "remdesivir",
                    "Lilly",
                    "COVID-19"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "Government to test remdesivir with Lilly drug in COVID-19 patients",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "NIH begins study of remdesivir with anti-inflammatory drug to treat COVID-19",
            "features": {
                "keywords": [
                    "NIH",
                    "remdesivir",
                    "anti-inflammatory",
                    "COVID-19"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "NIH begins study of remdesivir with anti-inflammatory drug to treat COVID-19",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes",
            "features": {
                "keywords": [
                    "Trulicity",
                    "dulaglutide",
                    "A1C",
                    "body weight",
                    "type 2 diabetes"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "5 Biopharmas Where BofA Would Put Its Money To Work",
            "features": {
                "keywords": [
                    "Biopharmas",
                    "BofA",
                    "investment"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "5 Biopharmas Where BofA Would Put Its Money To Work",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "Roundup",
                    "Q1 Earnings",
                    "BMY",
                    "NVO",
                    "PFE",
                    "RHHBY"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates",
            "features": {
                "keywords": [
                    "OPKO Health",
                    "Q1 Loss",
                    "Revenue Estimates"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Globus Medical (GMED) Misses on Q1 Earnings and Revenues",
            "features": {
                "keywords": [
                    "Globus Medical",
                    "Q1 Earnings",
                    "Revenues"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Globus Medical (GMED) Misses on Q1 Earnings and Revenues",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises",
            "features": {
                "keywords": [
                    "Omnicell",
                    "Q1 Earnings",
                    "Operating Margin"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top",
            "features": {
                "keywords": [
                    "Avanos Medical",
                    "Q1 Earnings",
                    "Estimates",
                    "Revenues"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results",
            "features": {
                "keywords": [
                    "DENTSPLY SIRONA",
                    "Q1 Preliminary Results"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "dental products"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook",
            "features": {
                "keywords": [
                    "Integra",
                    "Q1 Earnings",
                    "Outlook"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates",
            "features": {
                "keywords": [
                    "Glaukos",
                    "Q1 Earnings",
                    "Revenues"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "ophthalmology"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended",
            "features": {
                "keywords": [
                    "Bruker",
                    "Q1 Earnings",
                    "Guidance"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "scientific instruments"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline",
            "features": {
                "keywords": [
                    "Stock Charts",
                    "Bristol-Myers Squibb",
                    "Eli Lilly",
                    "GlaxoSmithKline"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates",
            "features": {
                "keywords": [
                    "Pacific Biosciences",
                    "Q1 Earnings",
                    "Estimates"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]